Tag: MCI-186

US OKs first new ALS treatment in more than 20 years

by Selina McKee | May 8, 2017 | News | 0

The US Food and Drug Administration has issued a green light for MT Pharma America’s Radicav, opening the door to the first new therapy for amyotrophic lateral sclerosis (ALS) in more than 20 years.

FDA to review Mitsubishi’s ALS drug

by Selina McKee | Jun 21, 2016 | News | 0

US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.